Immunogenicity up to age 5 years following a single-dose or two-dose infant primary series of 10-valent or 13-valent pneumococcal conjugate vaccine each followed by a booster dose in South Africa: extended follow-up of a single-centre, open-label, non-inferiority, randomised controlled trial

The Lancet Child & Adolescent Health · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles